NG-BIOTECH
16.7.2021 12:56:10 CEST | Business Wire | Press release
NG Biotech presents Ninonasal®, the COVID-19 antigen self-test that´s detecting Delta and Epsilon variants. Ninonasal® has obtained the CE mark and can now be marketed across Europe.
The highly sensitive Ninonasal® self-test is performed on nasal samples. Ninonasal®´s superior user friendliness supports the comfortable onsite testing, providing reliable results within minutes before leaving home. It even allows the testing of children under the supervision of adults.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210716005156/en/
Different from many other rapid tests, Ninonasal® already confirmed its ability to detect the most important variants of concerns clinically in European hospitals. Its unique test design allows the detection of the Alpha, Beta, Gamma, Delta and Epsilon variants. Therefore, Ninonasal® represents a precious and widely accepted tool for easy and frequent testing to detect positive cases and interrupt infections chains.
Obtaining CE marking
The Ninonasal® rapid test already proofed its performance since April 2021 under the special approval for home use from the French health authority. Now, with its CE mark for home use provided by a German notified body, it can be deployed in Europe within the framework of international distribution agreements.
In France, Ninonasal® is assembled into kits and distributed by Boiron Laboratories in order to strengthen its “fully made in France” character.
Milovan Stankov-Pugès, CEO of NG Biotech, says:
"Facing non-standardized local registration processes and products of doubtful quality and origin, distributors and public institutions across Europe were approaching us for help. With Ninonasal®, we did not just launch another rapid antigen test. It’s a solution for all those who understood that there is finally nothing more expensive than a cheap COVID test
".
About NG Biotech
Founded by a pioneer of the rapid test industry in 2012, NG Biotech is a French family owned company designing and manufacturing innovative in vitro diagnostic tools suitable for decision making in medical emergencies, in the laboratory and at the bedside.
NG Biotech innovation capabilities are powered by an expert R&D team backed by public-private scientific collaborations e.g. with the CEA (the French key player in technological research) and with multiple hospitals across Europe. NG Biotech proposes rapid tests in three main areas: Antimicrobial Resistance, Infectious Disease (COVID-19 tests) and Women's health (blood pregnancy self-tests). Our products are available in more than 70 countries, including Europe, USA and China.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210716005156/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom